Unicycive Therapeutics Inc (UNCY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Unicycive Therapeutics Inc (UNCY) has a cash flow conversion efficiency ratio of -0.266x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.03 Million) by net assets ($30.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Unicycive Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.
Unicycive Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Unicycive Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Unicycive Therapeutics Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Unicycive Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Unicycive Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Compañía Minera Autlán S.A.B. de C.V
MX:AUTLANB
|
0.022x |
|
American Rare EARTHS Ltd
AU:ARR
|
-0.027x |
|
CVC Brasil Operadora e Agencia
SA:CVCB3
|
0.373x |
|
Eastern Co
NASDAQ:EML
|
0.031x |
|
AB VILKUSKIU PIEN.EO 029
F:UDW
|
0.050x |
|
Corbus Pharmaceuticals Holding
NASDAQ:CRBP
|
-0.169x |
|
Parkit Enterprise Inc
V:PKT
|
0.019x |
|
Soc Centrale Bois Scieries Manche SA
PA:CBSM
|
0.037x |
Annual Cash Flow Conversion Efficiency for Unicycive Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Unicycive Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see UNCY stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $30.20 Million | $-31.32 Million | -1.037x | +73.03% |
| 2024-12-31 | $7.43 Million | $-28.57 Million | -3.845x | -180.11% |
| 2023-12-31 | $-3.81 Million | $-18.28 Million | 4.800x | -85.71% |
| 2022-12-31 | $-466.00K | $-15.65 Million | 33.586x | +9699.95% |
| 2021-12-31 | $16.48 Million | $-5.77 Million | -0.350x | -164.05% |
| 2020-12-31 | $-2.67 Million | $-1.46 Million | 0.546x | -58.94% |
| 2019-12-31 | $-884.00K | $-1.18 Million | 1.330x | +107.01% |
| 2018-12-31 | $-1.21 Million | $-775.00K | 0.643x | -- |
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester deriv… Read more